fbpx

ZEISS Introduces the Next Generation of Photochromic Lenses

ZEISS PhotoFusion X lenses darken and clear faster[1] while providing a new level of integrated blue light and UV protection

 A single pair of glasses for all light conditions instead of having to switch between two pairs, a clear and a dark, sun tinted pair when moving between outdoors and indoors. That’s what photochromic lenses have been offering for years. ZEISS PhotoFusion X is the new and improved generation of photochromic lenses based on an entirely new photochromic system. With this relaunch, transition speed is significantly improved. In addition, comprehensive blue light protection both in- and outdoors is provided by a new base lens material.

Performance optimized When light-reactive lenses are exposed UV radiation, billions of photochromic dyes in the lens begin to change their shape. This reaction causes the eyeglass lenses to darken. The latest ZEISS PhotoFusion X lenses use a completely new photochromic system with faster dyes in a robust yet more open carrier matrix. In numbers, this means ZEISS PhotoFusion X lenses darken up to 60 percent faster than the previous generation of ZEISS PhotoFusion[2].

It’s even more important for many eyeglass wearers that lenses clear fast when moving from outside to inside. That’s why special efforts were made to improve this process.

Maryam Karbalaei, the Marketing Manager of Zeiss Vision Care Canada confirms “Thanks to its fast reaction speed, PhotoFusion has been the preferred choice of many eye care professionals and consumers for over a decade. Now, in light of the growing demand, ZEISS set out to take light-reactive lenses to a whole new level – ZEISS PhotoFusion X. With new, fast-reacting photochromic dye compounds, a new speed-optimized carrier matrix, and even a new lens material, ZEISS PhotoFusion X is not merely a product update. It is photochromics re-envisioned, a product reinvented”.

ZEISS PhotoFusion X lenses offer the advantage of glare and UV protection outdoors without the need for separate glasses. It provides UV protection of up to 400 nanometers in any activation state, whether clear or dark. But what’s so unique about the new generation of self-tinting lenses? The new generation photochromic lenses are based on ZEISS BlueGuard lens material. The base material selectively absorbs UV radiation and potentially harmful blue light.

With the new generation of ZEISS PhotoFusion X lenses, there are also many attractive styles and color options available.

Currently, photochromic lenses account for more than eleven percent of all eyeglass lenses sold worldwide. The segment is growing twice as fast as the overall global market for eyeglass lenses.[3] And, North America is expected to dominate the overall photochromic lenses market by 2026. Canada with a 14.6% Photochromics Market share is one of the most potential and growing markets among North American countries. “With the significant improvement in the performance of our self-tinting eyeglass lenses, the increasing consumer awareness of blue light protection, and the new trendy options offered by the ZEISS PhotoFusion X portfolio, we are confident about the future of this eyeglass lens segment,” says Bryan Rossi, the President of Zeiss Vision Care Canada.

To learn more, click HERE

Click HERE for the press release.

This post is sponsored by Zeiss Vision Care Canada.


[1] compared to previous generation ZEISS PhotoFusion

[2] Analyses by Technology and Innovation, Carl Zeiss Vision GmbH, DE 2021 in accordance to ISO 8980-3. Based on the average speed (%T/min) of activation from clear state to 30%T at 23°C in grey 1.60 index and polycarbonate in HC only form.

[3] Strategy with vision: Consultants to eyewear and eyecare. World lens and frame demand study 2020. Germany: SWV, September 2020.

Featured Posts

Optometry Giving Sight logo a turquoise eye with black icons in the shape of people for the iris

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Read more
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Optometry Giving Sight logo a turquoise eye with black icons in the shape of people for the iris

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Read More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read More
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read More
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read More
Optometry Giving Sight logo a turquoise eye with black icons in the shape of people for the iris

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Read more
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Optometry Giving Sight logo a turquoise eye with black icons in the shape of people for the iris

Optometry Giving Sight Announces 2024 Grant Winners

This year, 16 grants totaling almost $1 million USD have been awarded to 15 organizations for projects that will help eradicate uncorrected refractive error globally.

Learn More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Read more
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more